Novel Drug Delivery Systems to Improve the Treatment of Keratitis

POLAT, Heybet Kerem; Kurt, Nihat; Aytekin, Eren; Pehlivan, Sibel Bozdağ; Çalış, Sema

doi:10.1089/jop.2021.0127

Cited by 8 publications

(4 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Viral keratitis is a common ophthalmic disease caused by various viruses, among which herpesviruses are the predominant etiologic agent (Koganti et al., 2021 ). So far, the treatment mainly relies on antiviral eye drops, and novel drug delivery systems are being developed due to eye barriers prevent drugs penetration (Polat et al., 2022 ). Varela-Garcia et al.…”

Section: Novel Contact Lenses In Ophthalmic Diseasesmentioning

confidence: 99%

Therapeutic applications of contact lens-based drug delivery systems in ophthalmic diseases

Zhao

Song

et al. 2023

Drug Delivery

View full text Add to dashboard Cite

Traditional ophthalmic drugs, such as eye drops, gels and ointments, are accompanied by many problems, including low bioavailability and potential drug side effects. Innovative ophthalmic drug delivery systems have been proposed to overcome the limitations associated with traditional formulations. Recently, contact lens-based drug delivery systems have gained popularity owing to their advantages of sustained drug delivery, prolonged drug retention, improved bioavailability, and few drug side effects. Various methods have been successfully applied to drug-loaded contact lenses and prolonged the drug release time, such as chemical crosslinking, material embedding, molecular imprinting, colloidal nanoparticles, vitamin E modification, drug polymer film/coating, ion ligand polymerization systems, and supercritical fluid technology. Contact lens-based drug delivery systems play an important role in the treatment of multifarious ophthalmic diseases. This review discusses the latest developments in drug-loaded contact lenses for the treatment of ophthalmic diseases, including preparation methods, application in ophthalmic diseases and future prospects.

show abstract

Section: Novel Contact Lenses In Ophthalmic Diseasesmentioning

confidence: 99%

Therapeutic applications of contact lens-based drug delivery systems in ophthalmic diseases

Zhao

Song

et al. 2023

Drug Delivery

View full text Add to dashboard Cite

show abstract

“…These can be defined as drug-loaded, thin, sterile, multilayered, solid or semi-solid consistency devices that are specifically designed (size and shape) to be placed in the lower or upper fornix or cornea [ 114 , 115 ]. These ocular devices can be formulated using insoluble polymers or soluble natural materials and can be developed as mucoadhesive or even soluble ocular drug inserts [ 116 ].…”

Section: Novel Formulation Strategies For Nat Ocular Deliverymentioning

confidence: 99%

“…There is a decrease in systemic absorption, reduction in dosing frequency and opportunity to target the internal eye tissues. Issues like difficulty in application or eye irritation due to rigidity lead to a reduction in patient compliance [ 115 , 118 ].…”

Section: Novel Formulation Strategies For Nat Ocular Deliverymentioning

confidence: 99%

Natamycin Ocular Delivery: Challenges and Advancements in Ocular Therapeutics

2023

View full text Add to dashboard Cite

Fungal keratitis, an ocular fungal infection, is one of the leading causes of monocular blindness. Natamycin has long been considered the mainstay drug used for treating fungal keratitis and is the only US Food and Drug Administration (USFDA)-approved drug, commercially available as a topical 5% w/v suspension. Furthermore, ocular fungal infection treatment takes a few weeks to months to recover, and the available marketed antifungal suspensions are associated with poor residence time, limited bioavailability (< 5%) and high dosing frequency as well as minor irritation and discomfort. Despite these challenges, natamycin is still the preferred drug choice for treating fungal keratitis, as it has fewer side effects and less ocular toxicity and is more effective against Fusarium species than other antifungal agents. Several novel therapeutic approaches for the topical delivery of natamycin have been reported to overcome the challenges posed by the conventional dosage forms and to improve ocular bioavailability for the efficient management of fungal keratitis. Current progress in the delivery systems uses approaches aimed at improving the corneal residence time, bioavailability and antifungal potency, thereby reducing the dose and dosing frequency of natamycin. In this review, we discuss the various strategies explored to overcome the challenges present in ocular drug delivery of natamycin and improve its bioavailability for ocular therapeutics.

show abstract

“…Stabilitelerinin düşük olmasının sebebi ise flokülasyon, koalesans (birleşme) ve krema-laşma gibi kararsızlık hâlleridir. 13 Bu stabilite problemlerinin önüne geçmek ve formülasyonların kinetik stabilitesini artırmak için emülsiyon formülasyonlarında yüzey aktif maddeler kullanılmaktadır. Fakat bu yüzey aktif maddelerin doz aralığının çok iyi bir şekilde ayarlanması gerekmektedir.…”

Section: Emülsiyonlarunclassified